Khishigjargal Batsukh

Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous NK cells combined with T lymphocytes in patients with recurrent solid tumors

Patients with advanced solid tumors who progress after standard therapies have limited treatment options. SDH-Combi is an autologous cellular immunotherapy integrating natural killer cells and tumor-primed T lymphocytes, designed to address tumor heterogeneity and immune escape t...